Potential conflicts of interest. The author certifies no potential conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Alicia N. M. Kraay
Epidemiology Department, Rollins School of Public Health, Emory University, Atlanta, GA, USA

References
1. Park S, Michelow IC, Choe YJ. Trend of gastrointestinal infections following nonpharmaceutical interventions, South Korea, 2020. J Infect Dis 2021; doi:10.1093/infdis/jia244
2. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global epidemiology of Campylobacter infection. Clin Microbiol Rev 2015; 28:687–720.
3. Ahmed SM, Lopman BA, Levy K. A systematic review and meta-analysis of the global seasonality of norovirus. PLoS One 2013; 8:e75922.
4. Cook SM, Glass RI, LeBaron CW, Ho MS. Global seasonality of rotavirus infections. Bull World Health Organ 1990; 68:171–7.
5. Grass JE, Gould LH, Mahon BE. Epidemiology of foodborne disease outbreaks caused by Clostridium perfringens, United States, 1998–2010. Foodborne Pathog Dis 2013; 10:131–6.
6. Lee MB, Greig JD. A review of nosocomial Salmonella outbreaks: infection control interventions found effective. Public Health 2013; 127:199–206.
7. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJ, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of enteric infections. Proc Natl Acad Sci 2020; 117:30547–53.

An Opportunity to Better Understand the Impact of Coronavirus on Immunocompromised Patients

Letter to the Editor—In my time as an epidemiology student, I have examined health outcomes and the overall impact of influenza on public health. This is why I read the recent article by Li et al [1] with great interest. The authors examined the outcomes of inpatients and outpatients with confirmed reverse transcription polymerase chain reaction (RT-PCR)-positive tests for influenza A or B or at least 1 of 4 common coronaviruses (229E, HKU1, NL63, and OC43) between June 2016 and February 2019, before the coronavirus disease 2019 (COVID-19) pandemic began to impact the United States. They found that patients with these common coronavirus infections had a higher risk of death and pneumonia than those with influenza, although there was no difference in intensive care unit admission rates. The authors examined the effects and distribution of covariates including comorbid conditions that have established associations with poor influenza and coronavirus outcomes, such as hypertension, type 2 diabetes, obesity, chronic ischemic heart disease, chronic kidney disease, and chronic lung disease. However, the authors did not examine another prominent condition that is related to severe influenza outcomes and could have an important association with coronavirus infections: immunocompromise.

A 2016 study found that the prevalence of immunocompromise in the United States is around 3%, making it fairly common [2]. Immunocompromise can result from a variety of causes including autoimmune disorders, human immunodeficiency virus (HIV), and treatments for conditions like cancer or solid organ transplant. While patients who are immunocompromised have significantly worse influenza outcomes [3, 4], the effect of immunocompromise on coronavirus outcomes is less clear. The authors chose the comorbid conditions they would include in this study based on a recent article that did not find cancer to be significantly associated with COVID-19 outcomes [5]. However, the Centers for Disease Control and Prevention still consider immunocompromised patients to be at increased risk for severe negative outcomes due to COVID-19 infection [6]. There is mixed evidence that both supports and refutes this association [7, 8]. The effect of immunocompromise on common coronavirus outcomes is also not well understood, although it seems that patients who are immunocompromised experience more severe outcomes [9]. Data on who is experiencing immunocompromise or who has an immunocompromised condition are available in ICD-10 codes and in electronic health records, which were the data sources in this study, so even if the available evidence was mixed, it seems that not including immunocompromised patients in this study was a missed opportunity to contribute to our understanding of the impact of immunocompromise on common coronavirus outcomes.

Coronaviruses were circulating in the population before COVID-19, and they will likely continue to circulate long after we have overcome the pandemic. Understanding the enhanced risks that immunocompromised people have regarding common coronavirus infections can serve to better protect this population from severe outcomes in the future, and contribute to the way we treat and assess risk for immunocompromised patients during this pandemic.

Notes
Financial support. The study was supported by grants from National Institute...
Potential conflicts of interest. The author reports no potential conflicts of interest. The authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Li D, Wolk DM, Cantor MN. Comparing clinical characteristics of influenza and common coronavirus infections using electronic health records [published online ahead of print 3 October 2020]. J Infect Dis doi: 10.1093/infdis/jiaa626.

2. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA 2016; 316:2547–8.

3. Collins JR, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011–2015. Clin Infect Dis 2020; 70:2121–30.

4. Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014; 58:214–24.

5. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369:m1966.

6. Centers for Disease Control and Prevention. If you are immunocompromised, protect yourself from COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/immunocompromised.html. Accessed 1 November 2020.

7. Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far [published online ahead of print 27 June 2020]. Clin Infect Dis doi: 10.1093/cid/ciaa863.

8. Addeo A, Friedlaender A. Cancer and COVID-19: unmasking their ties. Cancer Treat Rev 2020; 88:102041.

9. Liu DX, Liang JQ, Fung TS. Human coronavirus-229E, -OC43, -NL63, and -HKU1. Reference Module in Life Sciences 2020. doi:10.1016/B978-0-12-809633-8.21501-X.

Response to Letter to the Editor from Christina Parisi

TO THE EDITOR—We appreciate Ms Parisi’s recommendation [1] regarding investigating the role of immunosuppression in clinical responses to common coronaviruses and influenza. Although this is an intriguing topic, we did not include this as a variable in our analysis. One major challenge is accurately identifying immunosuppressed patients solely from electronic health record data; the Centers for Disease Control and Prevention criteria for immunosuppression, for example, include more than International Classification of Diseases codes and involve chart abstraction by surveillance officers [2]. As Ms Parisi notes, an approximation of immunosuppression may be derived using electronic health record data, so this may be part of our future work.

Note

Potential conflicts of interest. Both authors: No reported conflicts. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Correspondence: Michael N. Cantor, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 (michael.cantor@regeneron.com). The Journal of Infectious Diseases 2021; 224:372–3 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

References

1. Parisi C. An opportunity to better understand the impact of coronaviruses on immunocompromised patients. J Infect Dis 2020; doi: 10.1093/infdis/jiaa720.

2. Collins JR, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011–2015. Clin Infect Dis 2020; 70:2121–30.